Patients with severe coronavirus disease 2019 have high frequency of factor 5 Leiden and prothrombin gene mutations

Basit Öğe Kaydı
dc.authoridGezer, Sümbül/0000-0002-4800-4954
dc.authorwosidGezer, Sümbül/HNB-8204-2023
dc.contributor.authorAvcı, Burcu Altındağ
dc.contributor.authorDoğan, Mustafa
dc.contributor.authorBatar, Bahadır
dc.contributor.authorYıldırım, İlker
dc.contributor.authorSerdal, Elif
dc.contributor.authorGezer, Sümbül
dc.contributor.authorOnar, Çagatay L.
dc.date.accessioned2023-05-06T17:23:32Z
dc.date.available2023-05-06T17:23:32Z
dc.date.issued2023
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractWe investigated the frequency of factor 5 Leiden (FVL) and prothrombin gene (PTG) mutations in patients with severe coronavirus disease 2019 (COVID-19). Our primary aim is to reveal whether these mutations are associated with severity of disease and mortality. A total of 249 patients were included in this cross-sectional study. Severe COVID-19 cases (with oxygen saturation of less than 90 mmHg and who received ventilation support invasively or noninvasively) were included. FVL and PTG mutations were identified by real time- PCR technique. Frequency of mutations for FVL was 11.7%, whereas for PTG was 3.5%. The frequency of FVL and PTG's mutations in our patient group was found to be significantly higher than the normal population (P < 0.0001, 0.004, respectively). There was no difference in the frequency of mutations of FVL and PTG between the patients ventilated - invasively and noninvasively. There was also no difference in D-dimer, ferritin, fibrinogen, ex status, and entubational status between the groups of FVL and PTG mutated and wild-type. To the best of our knowledge, it is the first time that we have examined the frequencies of FVL and PGM's mutations in severe COVID-19 disease on such a large scale. The frequencies of both mutations in severe COVID-19 patients were higher than in the healthy population. We believe that studies prospectively designed, including asymptomatic and mild COVID-19 patients, will provide more comprehensive information on the subject.
dc.identifier.doi10.1097/MBC.0000000000001167
dc.identifier.endpage19
dc.identifier.issn0957-5235
dc.identifier.issn1473-5733
dc.identifier.issue1en_US
dc.identifier.pmid36165080
dc.identifier.scopus2-s2.0-85145641556
dc.identifier.scopusqualityQ3
dc.identifier.startpage14
dc.identifier.urihttps://doi.org/10.1097/MBC.0000000000001167
dc.identifier.urihttps://hdl.handle.net/20.500.11776/12127
dc.identifier.volume34
dc.identifier.wosWOS:000907668800003
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorAkpınar, Seval
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofBlood Coagulation & Fibrinolysis
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectFactor 5 Leiden
dc.subjecthereditary thrombophilia
dc.subjectprothrombin gene
dc.subjectsevere coronavirus disease 2019 infection
dc.subjectFactor-V-Leiden
dc.subjectVenous Thrombosis
dc.subjectD-Dimer
dc.titlePatients with severe coronavirus disease 2019 have high frequency of factor 5 Leiden and prothrombin gene mutations
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu